Araçlar ile Ekonomik etkinlikler ile ilgili alarm oluşturmak
ve takip ettiğiniz yazarların yayınları için kayıt olun.
Ücretsiz Kayıt Olun Hesabınız var mı? Giriş Yapın
74,34
-0,28
-0,38%
Kurlar
Tüm Araç Çeşitleri
- Tüm Araç Çeşitleri
- Endeksler
- Hisse Senetleri
- ETF'ler
- Fonlar
- Emtia
- Dövizler
- Kripto Para
- Tahviller
- Sertifikalar
Lütfen başka bir arama deneyiniz
💰 Buffett, Chubb'daki 6,7 milyar $ hissesini açıkladı. Tam portföyü InvestingPro ile sınırsız şekilde görüntüleyin Portföyü Kopyala
Janus Henderson Global Life Sciences Fund Class D (JNGLX)
Portföy'e Ekle/Kaldır
Portföye Ekle
Janus Global Life Sciences D
74,34
-0,28
-0,38%
- Genel Bakış
- Profil
- Geçmiş Veriler
- Varlıklar
JNGLX Genel Bakış
Bu sayfada Janus Henderson Global Life Sciences Fund Class D hakkında detaylı bir profile ulaşabilirsiniz. Yönetim, toplam varlıklar, yatırım stratejisi, iletişim bilgileri ve JNGLX için diğer bilgileri görüntüleyin.
İrtibat Bilgisi
Üst Düzey Yöneticiler
| İsim | Başlık | B.Tarihi | Bitiş |
|---|---|---|---|
| Daniel Lyons | Portfolio Manager | 2023 | Şimdi |
| Biyografi | "Daniel Lyons is a Portfolio Manager and Research Analyst at Janus Henderson Investors responsible for co-managing the Biotechnology strategy since 2018. Daniel started consulting for Janus in 1997 and joined the Health Care Sector Research Team full time in 2000. As a research analyst, he focuses on the biotechnology and life science tools sectors. Daniel received his bachelor of arts degree in biochemistry and chemistry from Rice University, graduating magna cum laude. He also earned a PhD from Stanford University’s programme in immunology and conducted postdoctoral research with a Nobel Laureate at the University of Colorado. He holds the Chartered Financial Analyst designation and has 19 years of financial industry experience." | ||
| Andy Acker | Portfolio Manager | 2007 | Şimdi |
| Biyografi | "Andy Acker is a Portfolio Manager at Janus Henderson Investors responsible for managing the Global Life Sciences and Biotechnology strategies since 2007 and 2018, respectively. He also leads the firm’s Health Care Sector Research Team. Andy was assistant portfolio manager on the Global Life Sciences strategy from 2003 to 2007. He joined Janus in 1999 as a research analyst focused on companies in the biotechnology and pharmaceutical industries. Prior to this, he worked as a strategy consultant for the Boston Consulting Group and as a health care analyst for Morgan Stanley Venture Partners. Andy received his bachelor of science degree in biochemical sciences from Harvard University, graduating magna cum laude and Phi Beta Kappa. He also earned an MBA with honours from Harvard Business School. Andy holds the Chartered Financial Analyst designation and has 23 years of financial industry experience." | ||
| Ethan Lovell | Portfolio Manager | 2016 | 2019 |
| Biyografi | Ethan Lovell is a Portfolio Manager at Janus Henderson Investors, responsible for co-managing the Global Life Sciences strategy, a position he has held since 2016. Prior to this, Mr. Lovell served as assistant portfolio manager on the strategy. He is also a Research Analyst, primarily focusing on the global pharmaceutical and medical device industries. Before joining Janus in 2007 as a research analyst, Mr. Lovell was a director at ClearBridge Advisors, covering companies in the pharmaceutical, biotechnology and medical device industries. Previously, he was managing director and founding partner of Saranac Capital, LP, where he was the health care sector portfolio manager. Mr. Lovell also worked at Salomon Brothers Asset Management as a director and later managing director of the health care team. He began his career at Bear, Stearns & Co. as an equity research analyst covering biotechnology, pharmaceuticals and life science tool companies. Mr. Lovell received his bachelor of arts degree, with a double major in chemistry and economics, from Bowdoin College and his MBA from Tulane University. He has 24 years of financial industry experience. Ethan Lovell is a Portfolio Manager at Janus Henderson Investors, responsible for co-managing the Global Life Sciences strategy, a position he has held since 2016. Prior to this, Mr. Lovell served as assistant portfolio manager on the strategy. He is also a Research Analyst, primarily focusing on the global pharmaceutical and medical device industries. Before joining Janus in 2007 as a research analyst, Mr. Lovell was a director at ClearBridge Advisors, covering companies in the pharmaceutical, biotechnology and medical device industries. Previously, he was managing director and founding partner of Saranac Capital, LP, where he was the health care sector portfolio manager. Mr. Lovell also worked at Salomon Brothers Asset Management as a director and later managing director of the health care team. He began his career at Bear, Stearns & Co. as an equity research analyst covering biotechnology, pharmaceuticals and life science tool companies. Mr. Lovell received his bachelor of arts degree, with a double major in chemistry and economics, from Bowdoin College and his MBA from Tulane University. He has 24 years of financial industry experience. Mr. Lovell received his bachelor of arts degree, with a double major in chemistry and economics, from Bowdoin College and his MBA from Tulane University. | ||
| Thomas R. Malley | Portfolio Manager | 1998 | 2007 |
| Biyografi | Malley joined Janus Capital Corporation in 1991 and currently serves as a portfolio manager. Malley holds the Chartered Financial Analyst designation. | ||
| Andy Acker | Portfolio Manager | 2006 | 2007 |
| Biyografi | "Andy Acker is a Portfolio Manager at Janus Henderson Investors responsible for managing the Global Life Sciences and Biotechnology strategies since 2007 and 2018, respectively. He also leads the firm’s Health Care Sector Research Team. Andy was assistant portfolio manager on the Global Life Sciences strategy from 2003 to 2007. He joined Janus in 1999 as a research analyst focused on companies in the biotechnology and pharmaceutical industries. Prior to this, he worked as a strategy consultant for the Boston Consulting Group and as a health care analyst for Morgan Stanley Venture Partners. Andy received his bachelor of science degree in biochemical sciences from Harvard University, graduating magna cum laude and Phi Beta Kappa. He also earned an MBA with honours from Harvard Business School. Andy holds the Chartered Financial Analyst designation and has 23 years of financial industry experience." | ||
Janus Henderson Global Life Sciences Fund Class D hakkında düşüncelerinizi yazın
Bu grafiği silmek istediğinize emin misiniz?
Sil İptal
Ekteki grafiği yeni bir grafikle değiştirmek istiyor musunuz?
Değiştir İptal
Yorum Kuralları
Yoruma Grafik Ekle
Engellemeyi Onayla
%USER_NAME% isimli kullanıcıyı engellemek istediğinize emin misiniz?
Bunu onayladıktan sonra %USER_NAME% isimli kullanıcı ile birbirinizin yorumlarını görmeyeceksiniz.
%USER_NAME% başarıyla Engelli Listesine eklendi
Bu kişinin engelini yeni kaldırdınız. Yeniden engellemek için 48 saat beklemeniz gerekmektedir.
Yorumu şikayet et
Yorum silinmeli, çünkü:
Yorum Şikayet Edildi
Teşekkürler!
Şikayetiniz yönetim ekibimize iletildi